Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07175805 für Symptome der unteren Harnwege, Stressharninkontinenz, Urge Urinary Incontinence, Überaktive Blase, Beckenorganprolaps, Gewichtsverlust, Stuhlinkontinenz, Bariatrische Chirurgie, glp1 Agonist ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy 200
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07175805 ist eine beobachtungsstudie zur Untersuchung von Symptome der unteren Harnwege, Stressharninkontinenz, Urge Urinary Incontinence, Überaktive Blase, Beckenorganprolaps, Gewichtsverlust, Stuhlinkontinenz, Bariatrische Chirurgie, glp1 Agonist und hat den Status noch nicht rekrutierend. Der Start ist für 1. Oktober 2025 geplant, bis 200 Teilnehmer aufgenommen werden. Durchgeführt von Hartford HealthCare wird der Abschluss für 1. Juni 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 16. September 2025 aktualisiert.
Kurzbeschreibung
The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understand...Mehr anzeigen
Ausführliche Beschreibung
Lower Urinary Tract Symptoms (LUTS) are defined as bothersome symptoms related to the storage of urine, voiding, and postvoid symptoms, and includes urgency, frequency, and urinary incontinence (UI). UI is the involuntary loss of urine and is a common and bothersome form of LUTS. The prevalence of urinary incontinence is high and increasing, with 61.8% of all women over 20 years old reporting urinary incontinence. Hi...Mehr anzeigen
Offizieller Titel
Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy
Erkrankungen
Symptome der unteren HarnwegeStressharninkontinenzUrge Urinary IncontinenceÜberaktive BlaseBeckenorganprolapsGewichtsverlustStuhlinkontinenzBariatrische Chirurgieglp1 AgonistWeitere Studien-IDs
- HHC-2025-0168
NCT-Nummer
Studienbeginn (tatsächlich)
2025-10
Zuletzt aktualisiert
2025-09-16
Studienende (vorauss.)
2027-06
Geplante Rekrutierung
200
Studientyp
Beobachtungsstudie
Status
Noch nicht rekrutierend
Stichwörter
lower urinary tract symtpoms
stress urinary incontinence
urge urinary incontinence
overactive bladder
pelvic organ prolapse
weight loss
fecal incontinence
bariatric surgery
glp1 agonist
stress urinary incontinence
urge urinary incontinence
overactive bladder
pelvic organ prolapse
weight loss
fecal incontinence
bariatric surgery
glp1 agonist
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Bariatric Surgery Patients who plan to undergo bariatric surgery | Bariatrische Chirurgie Patients in this arm plan to undergo gastric sleeve or gastric bypass surgery. |
GLP1 or GLP1/GIP1 Patients who plan to take GLP1 or GLP1/GIP1 medications | GLP1 receptor agonist Patients in this arm plan to start a GLP-1 receptor agonist. |
Hauptergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change in pelvic floor symptoms measured by survey the Urogenital Distress Inventory (UDI) | The investigators plan to measure the change in pelvic floor symptoms between woman taking glucagon-like peptide-1 receptor agonists (GLP1) medications vs women receiving bariatric surgery. These changes will be measured by validated survey, including the Urogenital Distress Inventory (UDI) | 6 months |
Change in pelvic floor symptoms measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8). | The investigators plan to measure the change in pelvic floor symptoms between woman taking glucagon-like peptide-1 receptor agonists (GLP1) medications vs women receiving bariatric surgery. These changes will be measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8). | 6 months |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Weiblich
Akzeptiert gesunde Freiwillige
Ja
- female
- 18-89 years old
- any race/ethnicity
- BMI ≥30 kg/m2
- current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic & Bariatric Surgery
- able/willing to give informed consent
- have a home scale to measure weight
Patients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm:
- prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1/gastric inhibitory peptide (GIP1)
- taking other weight loss agents (such as metformin)
Patients meeting all the following criteria will be eligible to participate in the bariatric surgery arm:
- plan to undergo gastric sleeve or gastric bypass surgery
- taking weight loss agents which are not GLP-1 RA or GLP-1/GIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1/GIP1 medications after surgery.
- Pregnant
- ≥90 years old
- <18 years old
- BMI <30 kg/m2
- A history of bariatric surgery prior to enrollment
- No home scale to measure weight
- Active cancer
Hartford HealthCareVerantwortliche Partei
Madeline Carmain, Hauptprüfer, Fellow, Urogynecology, Hartford HealthCare
Zentrale Studienkontakte
Kontakt: Madeline Carmain, MD, 860.972.4338, [email protected]
1 Studienstandorte in 1 Ländern
Connecticut
Hartford Hospital, Hartford, Connecticut, 06106, United States
Madeline Carmain, MD, Kontakt, 860-972-4338, [email protected]